Haemonetics Corporation Stock

Equities

HAE

US4050241003

Medical Equipment, Supplies & Distribution

Market Closed - Nyse 04:00:02 2024-06-03 pm EDT 5-day change 1st Jan Change
85 USD +1.09% Intraday chart for Haemonetics Corporation -3.78% -0.60%
Sales 2025 * 1.4B Sales 2026 * 1.48B Capitalization 4.32B
Net income 2025 * 153M Net income 2026 * 217M EV / Sales 2025 * 3.09 x
Net cash position 2025 * - Net cash position 2026 * - EV / Sales 2026 * 2.93 x
P/E ratio 2025 *
28.3 x
P/E ratio 2026 *
21.1 x
Employees 3,657
Yield 2025 *
2.35%
Yield 2026 *
2.35%
Free-Float 99.23%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.09%
1 week-3.78%
Current month+1.09%
1 month-9.96%
3 months+14.62%
6 months+0.88%
Current year-0.60%
More quotes
1 week
82.89
Extreme 82.885
89.01
1 month
82.89
Extreme 82.885
97.97
Current year
70.74
Extreme 70.74
97.97
1 year
70.74
Extreme 70.74
97.97
3 years
43.50
Extreme 43.5
97.97
5 years
43.50
Extreme 43.5
142.11
10 years
25.98
Extreme 25.98
142.11
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 16-05-15
Director of Finance/CFO 53 22-04-10
Chief Tech/Sci/R&D Officer - 06-07-31
Members of the board TitleAgeSince
Director/Board Member 69 17-10-17
Director/Board Member 69 14-07-22
Chairman 72 18-01-24
More insiders
Date Price Change Volume
24-06-03 85 +1.09% 660,242
24-05-31 84.08 -0.67% 948,051
24-05-30 84.65 -3.24% 757,809
24-05-29 87.48 -1.66% 944,572

Delayed Quote Nyse, June 03, 2024 at 04:00 pm EDT

More quotes
Haemonetics Corporation is a global healthcare company. The Company is engaged in providing a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Its technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The Company’s Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. Its Blood Center segment includes blood collection and processing devices and disposables for red cells, platelets and whole blood. The Company’s Hospital segment consists of Interventional Technologies, which includes vascular closure devices and sensor-guided technologies, and Blood Management Technologies, which includes devices and methodologies for measuring coagulation characteristics of blood, and blood transfusion management software, among others.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
85 USD
Average target price
113.5 USD
Spread / Average Target
+33.53%
Consensus